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Abstract
Background: Several pathways that control cell survival under stress, namely RNF8-dependent DNA damage recognition
and repair, PCNA-dependent DNA damage tolerance and activation of NF-kB by extrinsic signals, are regulated by the
tagging of key proteins with lysine 63-based polyubiquitylated chains, catalyzed by the conserved ubiquitin conjugating
heterodimeric enzyme Ubc13-Uev.
Methodology/Principal Findings: By applying a selection based on in vivo protein-protein interaction assays of compounds
from a combinatorial chemical library followed by virtual screening, we have developed small molecules that efficiently
antagonize the Ubc13-Uev1 protein-protein interaction, inhibiting the enzymatic activity of the heterodimer. In mammalian
cells, they inhibit lysine 63-type polyubiquitylation of PCNA, inhibit activation of NF-kB by TNF-a and sensitize tumor cells to
chemotherapeutic agents. One of these compounds significantly inhibited invasiveness, clonogenicity and tumor growth of
prostate cancer cells.
Conclusions/Significance: This is the first development of pharmacological inhibitors of non-canonical polyubiquitylation
that show that these compounds produce selective biological effects with potential therapeutic applications.
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Introduction
Modifications by ubiquitin (ubiquitylation) control the fate and
participation of proteins in fundamental biological processes [1].
The ubiquitylation of a protein involves the formation of a
isopeptide bond between a substrate lysine residue and the
carboxy terminal Gly76 on ubiquitin. Ubiquitin is activated by an
ATP-hydrolyzing ubiquitin-activating enzyme (Uba or E1), that
forms a high energy thioester bond between a Cys of its active site
and the carboxy terminus of ubiquitin. Activated ubiquitin is
transferred to a ubiquitin-conjugating enzyme (Ubc or E2) and a
thioester-linked E2-ubiquitin complex is formed. Finally, E2
interacts with a ubiquitin-protein ligase (E3), which conjugates
ubiquitin to the substrate protein and confers substrate specificity
to the pathway. Ubiquitin has several lysine residues that may be
substrates themselves of ubiquitylation, leading to the formation of
polyubiquitin chains. The signaling properties of ubiquitylation
vary according to the topology of polyubiquitin chains, which
depends on the particular lysine residue on the ubiquitin molecule
used to form these chains [2]. Thus, polyubiquitin chains linked
through K48 (often dubbed as ‘‘canonical’’) are recognized by
specific subunits of the 26S proteasome regulatory particle, leading
to the degradation of the modified protein [1,2]. Polyubiquitin
chains based on K63 are not as efficiently recognized by the
proteasome, and rather modify substrate proteins for interactions
with other proteins that participate in signaling and other
nonproteolytic processes [2,3]. The formation of this class of
‘‘non-canonical’’ polyubiquitin chains is mostly catalyzed by the
heterodimeric ubiquitin conjugating enzyme formed by Ubc13
and a Uev protein, Uev1 or Uev2/Mms2 in higher eukaryotes, or
Mms2 in the yeast S. cerevisiae [2,4,5]. The N-terminal alpha
helix of Uev1 (or Mms2) engages in high affinity interactions with
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the affinity and specificity of this interaction is Phe13 in Uev1,
which fits into a deep pocket formed by residues Glu55, Leu56,
Phe57 and Arg70 of Ubc13 [6,7,8]. Although other residues
contribute to heterodimerization, the above configuration ac-
counts for most of the specificity and affinity of the interaction
between Uev1 and Ubc13 [8,9,10].
In the yeast S. cerevisiae, DNA damage induces K63 poly-
ubiquitylation of the polymerase auxiliary factor PCNA, promot-
ing its function in the error-free DNA damage response pathway, a
process dependent on Ubc13 and Mms2 [11,12,13], which is
conserved in mammalian cells [14,15]. Of the two Uev proteins in
mammals, Uev2/Mms2, but not Uev1, appears to be specifically
involved in DNA damage repair [16]. The Ubc13-Uev2
heterodimer, recruited by the ubiquitin ligases RNF8 and
RNF168, also promotes the recruitment of the BRCA1 A DNA
damage repair complex, and K63 polyubiquitylation of histones
H2A and H2AX are critical in this process [12]. One of the best
studied processes regulated by K63 polyubiquitylation in mam-
mals are signaling pathways that activate the transcriptional factor
NF-kB [17]. Upon binding of TNF-a to its receptor, the RING
finger E3 ubiquitin ligase cIAP is recruited to the receptor complex
and ubiquitylates RIP1 possibly through Ubc13-dependent K63
polyubiquitination, resulting in the recruitment of LUBAC, and
the complexes TAK1/TAB2/TAB2 and NEMO/IKKa/IKKb
[18]. LUBAC drives linear polyubiquitylation of several compo-
nents of the TNF-R1 complex [19], which promotes the
stabilization of the complex [20] and is essential for the
recruitment of NEMO and activation of NF-kB [21]. Binding of
IL-1b to IL-1R recruits TRAF6 which oligomerizes, self-
polyubiquitylates in a reaction catalyzed by Ubc13-Uev1 and
recruits the TAK1/TAB2/TAB2 and NEMO/IKKa/IKKb
complexes. Both cytokines eventually activate a kinase cascade
that leads to the phosphorylation-dependent ubiquitylation and
degradation of IkB, allowing the nuclear translocation and
activation of NF-kB [17]. Recent evidence indicates that, in
addition to Ubc13, UbcH5 can also mediate K63 polyubiquityla-
tion of RIP, and that NF-kB activation by TNF-a may not be as
dependent on K63 polyubiquitylation as previously thought [22].
K63 polyubiquitylation is also critical for the activation of
additional signaling pathways [23,24], and has been shown to
regulate receptor endocytosis and processing [25,26], protein
sorting in the multivesicular body pathway [27], cell motility [28],
cell-cycle checkpoints [29], and autophagy [30].
Therefore, Ubc13-dependent K63 polyubiquitylation critically
regulates processes that generally enhance the survival of cells and
organisms in response to certain forms of stress, such as DNA
damage or exposure to infectious agents. A pharmacological
inhibitor of this modification would be useful not only to study the
proteins and biochemical and cellular processes that are modified
by this signal, but also to modulate these pathways for therapeutic
purposes: for instance, to sensitize cancer cells to DNA damaging
agents, or to blunt excessive immune activation.
Results
Development of antagonists of the Ubc13-Uev1
interaction
The hydrophobic grooves and pocket on Ubc13 that serve as its
interface with Uev1 present features of a candidate site for specific
and high-affinity occupancy by small molecules [31]: a relatively
small and deep surface, well-delimited by residues that are not
highly polar on the average. Preliminary docking analyses using a
comprehensive peptide-based structural library had suggested us
that this pocket could be effectively occupied by peptides with the
preferred consensus sequence NH3-X – Pro – b-strand aa (Val/
Leu/Ile/Arg/Cys) – hydrophobic/aromatic – X – Pro-COOH
(M. Murcia & A.R.O., unpublished observations). We reasoned
that peptidomimetic molecules capable of occupying this pocket
with sufficient affinity could compete with Uev1 for its interaction
with Ubc13, thereby inhibiting the enzymatic activity of the
heterodimer. We used a combinatorial chemical library based on
trimers of N-alkylglycines (peptoids) [32,33] as an initial source of
peptidomimetic structures. Peptoids are characterized by a peptide
scaffold with side chains attached to the backbone nitrogen atoms
[32], which confers them with several structural properties of
peptides [34,35], together with the desirable pharmacological
property of being more resistant to proteolytic enzymes [36]. The
combinatorial arrangement of N-substituted free amines provided
the necessary chemical diversity, and the positional scanning
format adopted for this particular library afforded a convenient
screening scheme with 52 pools, each containing 320 (pools 1–20)
or 256 individual peptoids (pools 21–52), for a total of 5,120
compounds [33]. Conformational flexibility greatly multiplies the
structural diversity provided by this library [37,38], a feature that
we deliberately chose in spite of the predicted detriment to high-
affinity interactions with specific targets of such flexible structures.
The general structure of the peptoid library used in this screening
is shown in Fig. 1A.
As a system to test the capacity of peptoids to inhibit the
interaction of Ubc13 with Uev1, we used the yeast-two hybrid
assay, since it permits to readily determine the specificity of the
inhibitory activities on a fully defined protein-protein interaction
and, simultaneously, it constitutes a stringent filter for the
bioavailability of active molecules. Yeast cells bearing interacting
human Ubc13 and Uev1 were used to screen the combinatorial
peptoid library pools for consistent and significant inhibition of this
interaction. As a control, an unrelated protein-protein interaction
was tested, that of p53 with SV40 large T. Of the 52 pools, those
numbered 12, 36 and 46 produced the greatest inhibitory activity
on the Ubc13-Uev1 interaction, without significant inhibition on
the control p53-large T interaction (Fig. 1B). Deconvolution of the
selected pools (i.e., 12 and 16 from the sublibrary where R1 was
known, 36 from the sublibrary where R2 was known, and 42 and
46 from the sublibrary where R3 was known) indicated that the
inhibitory activity corresponded to four preferred structures
(Fig. 1C). The selected amines in these peptoids are: at position
R1, either 49-fluorophenylethyl (peptoid N37-37-9C) or 29-49-
dichlorophenylethyl (N15-37-13C); at position R2, 49-fluorophe-
nylethyl; at position R3, either 49-methoxyphenylethyl (N37-37-
13C and N15-37-13C) or 2-(29-pyridyl)ethyl (N37-37-9C and
N15-37-9C).
Our hypothesis is that these peptoids inhibit the Ubc13-Uev1
interaction by occupying the Ubc13 dimerization interface with
Uev1. Therefore, we analyzed whether these molecules fit onto the
Ubc13 surface by means of molecular docking. Because of the
inherent flexibility of the carbon framework and N-substituted
bonds in alkylglycines, the selected peptoids present a high degree
of conformational heterogeneity. To reduce this conformational
flexibility, we evaluated 8 families of cyclic structures that are
relatively more rigid than the planar equivalents of the selected
peptoids, with the added feature that they are readily suitable for
synthesis following standard chemical procedures. All energetically
favourable spatial arrangements for these structures were com-
puted. Of the 8 families of cyclic structures, six had 4 enantiomers
and two had 2 enantiomers, and each molecule had between 10
and 14 torsional angles. Thus, the total number of ligands
generated was <5610
6. This small structural library was subjected
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Ubc13. For each ligand, the energetically most favourable
orientations for interaction with the Ubc13 surface were computed
and ranked with CDOCK [39] (Tables S1 and S2). The ligands
with the most favourable interactions corresponded to conformers
of cyclic families I and II, both derived from peptoid N37-37-9C.
Figures 2A and 2B show Connolly surface representations of the
computed interactions of these two compounds with Ubc13. These
two structures differ mainly in their cyclical components, with
either seven (family I) or six (family II) atom rings, that occupy the
center of the hydrophobic pocket on Ubc13, with the side chains
adapting with favorable interaction energies to the three grooves
that stem from the pocket (Fig. 2A and B). These models suggest
that family I compounds have more favorable interaction energies
on Ubc13 than family II compound (Tables S1 and S2).
In vitro activities of Ubc13-Uev1 antagonists
Two cyclic compounds were synthesized on the basis of the
structures selected from the virtual screening, and designated
hereafter Ia (family I) and IIa (family II) (Fig. 2C and 2D). Both
compounds interfered with the Ubc13-Uev1 interaction at
micromolar concentrations on yeast two-hybrid assays (Fig. S1).
In competition assays with recombinant proteins, compound Ia
inhibited the Ubc13-Uev1 interaction at nanomolar concentra-
tions, and compound IIa at micromolar concentrations (Fig. 3A).
These actitivies were specific to these two compounds, since an
unrelated control cyclic compound with a similar ring structure
(of the family I type) did not detectably interfere with the
Ubc13-Uev1 interaction at the same concentrations (Fig. 3A).
This activity was quantitated by surface plasmon resonance
(SPR). With this technique, the dissociation constant for the
Ubc13-Uev1 interaction was 1.0610
29 M, indicating a high-
affinity binding of the heterodimer, with values close to those
reported by isothermal titration calorimetry [40] that are
expected to require high affinity binding by any potential
competitor. SPR determinations yielded a IC50 of 1.0610
211 M
for compound Ia, and of 1.1610
26 M for compound IIa
(Fig. 3B), indicating a significantly more effective inhibition of
the Ubc13-Uev1 interaction by compound Ia. They also
indicated that the binding of the two active compounds on
Ubc13 must occur at high affinities, in order to successfully
compete with the high affinity Ubc13-Uev1 interaction. To
determine the binding efficiency of these compounds to Ubc13,
lysine-conjugated derivatives (Fig. S2) were immobilized on SPR
sensor chips, and Ubc13 subsequently applied in the mobile
phase. These assays yielded dissociation constants for Ubc13 of
4.4610
212 M for compound Ia and of 4.68610
27 Mf o r
compound IIa (Figure 3C). This low dissociation constant for
compound Ia reinforces the conclusion that it specifically
occupies with high affinity the Ubc13 interface normally used
to interact with Uev1, and that this is the likely mechanism by
which it antagonizes this interaction.
Figure 1. Peptoid combinatorial libraries as sources of structures that antagonize protein-protein interactions. (A) General structure
of the combinatorial N-alkyl glycine library. (B) Yeast two-hybrid screening for peptoid pools that inhibit the Ubc13-Uev1 interaction. As a control
interaction, the p53-large T interaction was assayed with the same pools in parallel assays. The b-galactosidase activity was normalized to the values
for the control interaction, and to the values for the Ubc13-Uev1 interaction in the presence of solvent only (without peptoids). (C) Structures of the
individual peptoids inferred as the most likely active inhibitors of the Ubc13-Uev1 interaction.
doi:10.1371/journal.pone.0011403.g001
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of Ubc13-Uev1 was tested in polyubiquitin chain extension
reactions with defined components. In these reactions, the
substrate was either wild-type ubiquitin or a variant ubiquitin in
which all Lys residues, except at positions 63 or 48, were mutated
to Arg (UbK63 or UbK48). The Ubc13-Uev1 dimer, but not
either protein alone, supported the formation of free polyubiquitin
chains of increasing lengths with either form of ubiquitin as a
substrate (Fig. 3D) with robust kinetics (Fig. 3E). Addition of
compound Ia strongly inhibited this reaction (Fig. 3D and E). In
control experiments, the UbK48 mutant was not a substrate for
free polyubiquitin chain extension by Ubc13-Uev1 (Fig. 3F), which
supports the specificity of the Ubc13-Uev1 heterodimer for K63-
only ubiquitin. Neither compound affected the in vitro Ubc4/5-
dependent polyubiquitylation of proteasomal components (Fig.
S3), supporting that they specifically target Ubc13 and not other
E2 enzymes with canonical (K48) polyubiquitylation activities.
Therefore, compound Ia is a potent disruptor of the interaction
between Ubc13 and Uev1, and an effective inhibitor of K63
polyubiquitylation catalyzed by Ubc13-Uev1.
Effects of compound Ia on cellular pathways regulated
by K63 polyubiquitylation
Both compound Ia and compound IIa were shown to efficiently
enter cultured human cells, as determined by HPLC of cytosolic
lysates (not shown) and by microscopic localization of fluorescei-
nated derivatives of the compounds (Fig. S4 and S5). To test
whether compound Ia could disrupt the Ubc13-Uev1 interaction
in vivo, HeLa cells were incubated with compound Ia, lysed and
subjected to co-immunoprecipitation. It can be seen (Fig. 4A) that
incubation with compound Ia significantly inhibited the abun-
dance of the Ubc13-Uev1 heterodimer in HeLa cells.
The activation of NF-kB by extracellular signals is regulated by
Ubc13-dependent K63 polyubiquitylation in HEK293T and other
epithelial cells [41], but not in immune cells [24]. Preincubation of
HeLa cells with compound Ia prevented the downregulation of
IkB by TNF-a in a dose-dependent manner, with strong effects at
concentrations as low as 10 nM (Fig. 4B), an evidence of its activity
as an antagonist of NF-kB activation induced by TNF-a in these
cells. Compound Ia also inhibited the phosphorylation of IKKa/b
induced by TNF-a in HeLa cells (Fig. 4B), consistent with the
known role of Ubc13 in TNF-a signaling upstream from the IkB
kinases [41]. In addition, compound Ia also strongly inhibited in a
dose-dependent manner the nuclear translocation of a GFP form
of p65 (a subunit of NF-kB) by TNF-a in HeLa cells (Fig. 4C).
We tested the effect of compound Ia on a second pathway
regulated by K63-linked polyubiquitylation. Thus, compound Ia
inhibited the UV-induced K63 polyubiquitylation of PCNA in vivo
(Fig. 5A), although the effects were evident only when cells were
exposed to relatively high concentrations of the compound
(100 mM). In control experiments, the UV-induced K63-depen-
dent polyubiquitylation of PCNA was inhibited by transfection
with a dominant-negative form of Ubc13 (Ubc13
C87A), indicating
that this modification of PCNA indeed requires enzymatically
active Ubc13 (Fig. S6).
Chemosensitization of mammalian cells by a
compound Ia
Given the role of K63 polyubiquitylation in DNA damage
recognition and repair and NF-kB signaling, we reasoned that
mammalian cells exposed to compound Ia might show increased
sensitivities (decreased survival) to DNA damaging agents. PC-3
prostate cancer cells and HeLa cells were exposed to increasing
doses of the topoisomerase II inhibitors etoposide or doxorubicin,
respectively, which induce double-strand breaks in DNA, in the
presence of compound Ia. In PC-3 cells, treatment with 100 mM
compound Ia decreased the LD50 for doxorubicin from 0.55 mM
to 0.1 mM (5.5-fold sensitization, Fig. 5B), and in HeLa cells,
compound Ia decreased the LD50 for etoposide from 2.5 mMt o
0.2 mM (12.5-fold sensitization, Fig. 5C).
Effects of compound Ia on the growth and invasiveness
of cultured cells
Compound Ia did not significantly inhibit the growth on plastic
substrate of HeLa cells under standard growth conditions (Fig. S7),
suggesting a low direct cytotoxicity on a range of cell types. In
contrast, it significantly inhibited colony formation in soft agar of
highly metastatic and clonogenic PC-3/M cells at low micromolar
concentrations (Fig. 6A, left panel), and it inhibited the in vitro
invasiveness through extracellular matrix of parental PC-3
prostate cancer cells also at low micromolar concentrations
(Fig. 6A, right panel). Neither compound Ia, nor the less active
compound IIa, significantly affected the growth or differentiation
of human endothelial cells in vitro (data not shown).
Antitumoral activity of compound Ia in a mouse
xenograft model
The chemosensitizing effect of compound Ia could be caused
either by an inhibitory activity on DNA repair, a diminished
activation of NF-kB, or a combination of both activities.
Compound Ia also inhibits the clonogenicity and invasiveness of
PC-3 cells. We next tested the in vivo antitumoral activity of this
compound. PC-3 prostate cancer cells, bearing a stably integrated
luciferase gene under the control of a constitutive promoter [42],
were grafted into the rear extremities of Balb/c nude mice.
Tumor-bearing mice were injected intravenously with doxorubicin
(5 mg/Kg, weekly), combined, or not, with intratumoral injections
Figure 2. Selection of cyclic structures with optimal fitting on
Ubc13 by large-scale molecular docking. (A, B) Connolly surface
representation of Ubc13 along with the conformers of cyclic structures with
highest ranked energy and fitting values for docking on the surface of
Ubc13 (A, family I cyclicization mode, enantiomer 2; B,f a m i l yI Ic y c l i c i z a t i o n
mode, enantiomer 1). C, Structure of cyclic compound Ia, synthesized after
the structure for family I cyclic molecules, derived from peptoid N37-37-9C.
D, Structure of cyclic compound IIa, synthesized after the structure for
family II cyclic molecules, derived from peptoid N37-37-9C.
doi:10.1371/journal.pone.0011403.g002
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PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11403Figure 3. In vitro activities of compounds Ia and IIa. (A) Inhibition of the Ubc13-Uev1 interaction by compounds Ia and IIa, determined by GST-
pull-down assays. Matrix-bound GST-Ubc13, preincubated with the test or control compounds at a final concentration of 100 nM, were allowed to
interact with recombinant Uev1. Fraction E corresponds to the eluted fraction of Uev1. Fraction B corresponds to the Uev1 that remaind bound to
GST-Ubc13, and that are eluted with reduced glutathione. All fractions were assayed by Western blotting with anti-Ubc13 and anti-Uev antibodies. (B)
Surface plasmon resonance Ubc13-Uev1 binding competition assay. Ubc13 was pre-incubated with varying concentrations of compounds Ia or IIa
and injected into a CM5 chip on which Uev1 had been immobilized. The IC50 for binding inhibition was 10 pM for compound Ia, and 1.1 mM for
compound IIa. (C) Surface plasmon resonance sensorgrams for the interaction of UBC13 with immobilized compound Ia (top) or IIa (bottom). Lysine
derivatives of either compound were immobilized onto CM chips, and Ubc13 was run in the mobile phase at the indicated concentrations. From the
signals, dissociation constants for Ubc13 were calculated, (4.4610
212 M for compound Ia and 4.68610
27 M for compound IIa). (D) Effect of
compound Ia on in vitro wild-type ubiquitin free chain elongation dependent on Ubc13 and Uev1. Purified recombinant proteins (E1, Ubc13, Uev1)
were used to synthesize free ubiquitin chains for the indicated times, in the absence (Control) or presence of compound Ia (1 mM). Ubiquitin chains
were detected by Western blotting with anti-ubiquitin. (E) Graphic representation of the kinetic experiment shown in (D), with quantitation of the
accumulated levels of triubiquitin (Ub3) free chains. (F) Effect of compound Ia on in vitro chain elongation of K63- or K48-only ubiquitin mutants. The
experiment was performed as in (D), except that mutant ubiquitins were substituted for the wild-type form.
doi:10.1371/journal.pone.0011403.g003
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a week). A third group of mice received intratumoral compound Ia
and no doxorubicin. Control mice were sham injected with
phosphate-buffered saline by both routes. After 8 weeks of
treatment, control mice had grown extensive tumors at the site
of grafting (Fig. 6B, C). In contrast, mice receiving doxorubicin
alone, compound Ia alone, or a combined treatment of systemic
doxorubicin and local (intratumoral) compound Ia had signifi-
cantly reduced tumors as compared to control mice, by the end of
the treatment (Fig. 6B, C). Analysis of the corresponding
quantitative data (normalized photon counts) showed that the
average sizes of the tumors at the end of the experiment were
24.7% of control tumors for mice treated with compound Ia alone,
22.0% for mice treated with doxorubicin alone, and 15.5% for
mice with the combined treatment (Fig. 6C), the differences
between the three treatment regimes not being statistically
significant. There were no evidences of acute or chronic toxicity
either at the site of injection or in other organs and tissues
associated with the administration of compound Ia (unpublished
observations). Therefore, administration of compound Ia alone
significantly limits the growth of PC-3 prostate cancer xenografts,
to a degree comparable to treatment with the chemotherapeutic
agent doxorubicin.
Discussion
In terms of drug design, the specific contribution of our
approach has been to use in vivo screenings to find hit structures
from a combinatorial chemical library, and to further select the
best ligands by virtual screening. Our drug development scheme
should be applicable to the design of small molecules capable of
specifically interfering with many other well-characterized inter- or
intra-molecular interactions with amenable surfaces [31]. Other
non-peptide small molecules that disrupt specific protein-protein
interactions have been successfully developed in recent times
[43,44,45,46,47], and they are beginning to show great promise
for the therapy of human cancer. In practical terms, we have
developed small molecules that can effectively and selectively
antagonize the Ubc13-Uev1 interaction and inhibit K63 poly-
ubiquitylation in both yeast and mammalian cells, and we have
shown that these compounds can be used in combination therapy
schemes as antitumoral agents in cultured and animal models of
cancer.
Specifically, compound Ia sensitizes PC-3 prostate cancer cells
to the antiproliferative activity of doxorubicin in cultured cells and
it shows direct antitumoral activity in mouse tumor xenografts. A
number of mechanisms can be at play to cause increased
sensitivities of tumor cells to chemotherapy or radiotherapy,
including inhibition of NF-kB [48], downregulation of transporters
of the MDR family [49] or the Akt-mTOR pathway [50,51,52].
The evidence provided here suggests that at least two mechanisms
may be relevant for the increased sensitivity to doxorubicin caused
by compound Ia, namely inhibition of NFk-B activity and
compromise of DNA repair. The demonstration that this
compound disrupts the interaction between Uev1 and Ubc13
provides a mechanistic explanation for its inhibitory activity on the
NF-kB signaling pathway [17]. Recently, it has been shown that
another ubiquitin conjugating enzyme, UbcH5, can promote K63
polyubiquitylation, and that NF-kB activation by IL-1b is much
more strongly dependent on Ubc13-dependent K63 polyubiqui-
tylation than activation by TNF-a [22]. However, a large body of
literature strongly suggests a critical role of Ubc13 and K63
polyubiquitylation in the activation of NF-kB not only by IL-1b
but also by TNF-a. In this regard, the chain type of ligand-induced
Figure 4. Inhibition of NF-kB signalling by compound Ia. (A)
Compound Ia inhibits the formation of Ubc13-Uev1 heterodimers in
vivo. HeLa cells were co-transfected with FLAG-Ubc13 and HA-Uev1,
treated with different concentrations of compound Ia, lysed and
subjected to co-immunoprecipitation. It can be seen that incubation of
cells with increasing concentrations of compound Ia leads to decreasing
amounts of Uev1 that can be co-immunoprecipitated with Ubc13. (B)
Dose-dependent inhibition by compound Ia of NF-kB activation by TNF-
a. HeLa cells were stimulated for 15 min with TNF-a (20 ng/mL) without
(0) or with overnight preincubation with the indicated final concentra-
tions of compound Ia, and analyzed by Western blotting for IkB protein
levels or for phosphorylation of IKKa/b.( C) Dose-dependent inhibition
by compound Ia of the nuclear translocation of p65-GFP induced by
TNF-a. HeLa cells were transfected with p65-GFP were incubated
overnight with varying concentrations of compound Ia, treated with
TNF-a (20 ng/mL) for 30 min, fixed and cells counted for nuclear
localization of p65-GFP. Background (proportion of cells with nuclear
p65-GFP in untreated samples) was subtracted, and values normalized
against the proportion of cells with nuclear p65-GFP in cells stimulated
with TNF-a only.
doi:10.1371/journal.pone.0011403.g004
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been determined, and, given the recruitment of Ubc13 by cIAP, it
is quite possible that such chains are of the K63 type.
Furthermore, mice haploinsuficient for Ubc13 display cell-type-
specific defects in chemokine and NF-kB signaling [53],
supporting a critical role of Ubc13 and K63 polyubiquitylation
in the activation of NF-kB by different stimuli in vivo, including
TNF-a and LPS. Our observations showing that the small
molecule antagonist of Ubc13-Uev interactions compound Ia
inhibits NF-kB activation by TNF-a would also support a role for
Ubc13 in this pathway. Alternative explanations would include the
possibility that our compounds inhibit other ubiquitin conjugating
enzymes or additional components of the TNF-a signaling
cascade, which has not been formally ruled out in the present
study.
On the other hand, it has also been shown that unanchored
K63-linked polyubiquitin chains are essential for the activation of
the RIG-I pathway in response to viral infection, and that both
Ubc13 and Ubc5 are required in this pathway [54,55]. Therefore,
the inhibition of Ubc13 by small compounds could limit the
response to viral infections mediated through this pathway.
Regarding the role of Ubc13 and K63 polyubiquitylation in
DNA damage response, the very high similarity of Uev2 (Mms2) to
Uev1, and the computed interaction of compound Ia on the
hydrophobic pocket of Ubc13, allows to predict with sufficient
confidence that this compound should disrupt also the interaction
of Uev2 (Mms2) with Ubc13. Indeed, we have shown that
compound Ia inhibits the UV-induced K63 polyubiquitylation of
PCNA, a modification that requires Ubc13-Uev2 [11,15,16].
Therefore, the predicted disruption of the Ubc13-Uev2 heterodi-
mer should be associated with a compromise in tolerance to DNA
damage by radiation or radiomimetic drugs in mammalian cells
[16]. Additional mechanisms, not explored here but possibly also
involved in the chemosensitization caused by compound Ia, could
be related to the regulation by Ubc13 of double-strand DNA
damage recognition and repair through its interaction with the
ubiquitin ligase RNF8 [12]. The fact that we have observed
inhibition by compound Ia of K63 polyubiquitylation of PCNA
only at high concentrations of the compound may suggest either
that the compound, although it enters the cells, does not reach the
nucleus efficiently, or that K63 polyubiquitylation of PCNA can be
catalyzed in mammalian cells by other ubiquitin conjugating
enzymes in addition to Ubc13. This may also be the case for K63
polyubiquitylation associated with damage foci in response to
DNA double-strand breaks [56]. Indeed, in immunofluorescent c-
H2AX focus assays, the same batches of compound Ia that
inhibited NF-kB activation at low micromolar concentrations only
modestly inhibited the maintenance of c-H2AX in ionizing
radiation-induced foci (data not shown). Given the limited effects
of compound Ia on both PCNA K63-linked polyubiquitylation
and on DNA damage focus formation and resolution, it is possible
that the chemosensitization to doxorubicin and etoposide observed
in PC-3 and HeLa cells may be better explained by its inhibitory
effects on NF-kB signaling.
We have observed that compound Ia exerts a direct antitumoral
activity in a PC-3 mouse xenograft tumor model. This compound
Figure 5. Chemosensitizing activity of compound Ia. (A)
Inhibition by compound Ia of UV-induced K63-dependent polyubiqui-
tylation of PCNA. HEK-293T cells, transfected with a construct
expressing HA-tagged K63-only mutant ubiquitin, were pretreated (Ia)
or not (Control) overnight with 100 mM of compound Ia, irradiated or
not with UV light (60 J/m
2), lysates immunoprecipitated with anti-PCNA
and blotted with anti-HA. The immunoprecipitates were blotted in
parallel with anti-PCNA for loading control (PCNA, lower panel).
Arrowhead, position cooresponding to monoubiquitylated PCNA. (B
and C) Sensitization by compound Ia to doxorubicin-induced
cytotoxicity in mammalian cells. PC-3 prostate cancer cells (B) and
HeLa cervical cancer cells (C) were exposed to varying concentrations of
doxorubicin or etoposide, with or withoud compound Ia (100 mM).
Viable cell numbers were determined with the CyQuant assay after 72 h
(PC-3 cells) or 48 h (HeLa cells) of treatment.
doi:10.1371/journal.pone.0011403.g005
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tested, but it inhibited the invasiveness of PC-3 cells through
extracellular matrix in Boyden chamber experiments, and also
inhibited the formation of colonies in 3-dimensional soft-agar
cultures. The NF-kB pathway is known to play a prominent role in
promoting invasiveness [57,58], being constitutively active in PC-3
cells [59], and thus the observed inhibition of in vitro invasiveness
by compound Ia could be one of the consequences of the
inhibition of NF-kB activation by this compound. Clonogenicity in
soft agar is associated with the capacity of cells for self-renewal,
and tends to correlate well with tumorigenicity in vivo. This
property, exhibited by distinct cellular subpopulations in some
tumors, is not necessarily positively correlated with NF-kB activity
[60], and thus the inhibition by compound Ia of the clonogenicity
of PC-3 cells could reflect a requirement for Ubc13 activity in
other pathways regulating the self-renewal capacity of these cells.
In any case, the sum of both activities of compound Ia could
explain at least part of the observed direct antitumoral effect.
In summary, we have developed specific and potent small
molecule antagonists of the Ubc13-Uev1 interaction that inhibit
the enzymatic activity of this heterodimer, K63 polyubiquitylation,
and we have shown that one of these molecules produces
significant effects in the activation of NF-kB by TNF-a, and in
invasiveness and clonogenicity in vitro and tumorigenicity of cancer
cells in vivo. Based on these activities, we anticipate that tese
compounds should be useful to probe other biochemical pathways
and cellular processes regulated by K63 polyubiquitylation and to
test their effects in relevant models of human pathologies in which
these processes are dysregulated.
Materials and Methods
Synthesis of trialkylglycine-based combinatorial mixtures
and of individual compounds
An optimized library of 5,120 peptoids in 52 controlled
mixtures was synthesized by using the positional scanning format
on solid phase [33] (Supporting Methods S1).
Yeast two-hybrid
Plasmids pBD-Ubc13 and pACT2-Uev1 were co-transfected
into the S. cerevisiae strain AH109 in quadruple selection
medium. After 3 days, colonies positive for the Ubc13-Uev1
interaction were subjected to liquid culture assays of b-galactosi-
dase activity using ONPG as the substrate, in the presence of
0.1 mM of peptoid-mix from each peptoid-pool. One unit of b-
galactosidase was defined as the amount which hydrolyzed 1 mmol
O-nitrophenol D-galactose per min per cell.
Docking
Docking was performed using the crystal structure of the
Ubc13-Mms2 complex (entry 1JAT in the Brookhaven Protein
Data Bank). From the heterodimeric complex, chain A (Ubc13)
was selected as the receptor (Supporting Methods S1).
Protein-protein binding assays
Purified GST-Ubc13 (1 mg) was bound to glutathione-Sephar-
ose, washed and preincubated for 1 h with varying concentra-
tions of compounds Ia IIa, or a control cyclic compound, and
then allowed to bind Uev1 (1 mg) for 1 h in a buffer containing
50 mM Tris-HCl pH 7.6, 0.1 mM EDTA, 150 mM NaCl and
0.2 mM DTT. Unbound fractions were collected, the beads
washed 5 times with the same buffer, and finally incubated
with glutathione elution buffer. Fractions were resolved by
Figure 6. Effect of compound Ia on the growth and tumorige-
nicity of PC-3 prostate cancer cells. (A) Inhibition by compound Ia of
the invasiveness through Matrigel of PC-3/luc cells (left panel) and of the
clonogenicity in soft agar of PC-3/M cells (right panel). Error bars
correspond to standard deviations for values obtained in triplicate
experiments. (B) Activity of compound Ia in a mouse tumor xenograft
model. Balb/c nu/nu mice were grafted with luminescent PC-3/luc cells
on both rear extremities.After tumors haddeveloped at the grafted sites,
mice were placed in 4 groups. A control group received only
intratumoural injections of PBS. A group was treated intravenously with
doxorubicin (5 mg/Kg/week). A third group was treated with compound
Ia, (100 mM intratumoral, twice a week). A fourth group was treated both
with doxorubicin (5 mg/Kg/week) and compound Ia (0.15 mg/Kg
intratumoral, twice a week). (C) Quantitative data analysis (relative light
units)corresponding to6 tumors (3mice)foreach treatment group.RLUs
were normalized in each group relative to values for day 0.
doi:10.1371/journal.pone.0011403.g006
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with specific antibodies [61].
Surface plasmon resonance
Recombinant Uev1 protein was immobilized on a Biacore CM5
Chip. The final response obtained was 1179,1 RU (response units)
(1 response unit corresponds to 1 pg of protein per mm
2)o f
immobilized Uev1. Purified Ubc13 was maintained at 400 nM in
running buffer (10 mM HEPES, 0.15 M NaCl, pH 7.4). Ubc13
was preincubated with the test compounds at varying concentra-
tions, and interaction assays run in a Biacore T100 instrument.
In vitro ubiquitylation
Purified Ubc13 (0.2 mM), Uev1 (0.2 mM), and E1 (0.1 mM,
Boston Biochem) were incubated in 50 mM Tris-HCl, 5 mM
MgCl2, 2 mM ATP and 0.5 mM DTT, with either 117 mM wild-
type ubiquitin (Biomol), 6 mM UbK48_only or 6 mM Ub-
K63_only (Boston Biochem). To determine the effects of
compounds Ia and IIa, Ubc13 was pre-incubated for 10 min at
room temperature with 1–100 mM of either compound. The
reactions were allowed to proceed for the indicated times and
stopped by addition of SDS-PAGE sample buffer and boiling. The
reaction products were detected by Western blotting with a rabbit
anti-ubiquitin antibody (Biomol).
Cell culture
HeLa and HEK293T cells were obtained from the American
Type Culture Collection (Manassas, VA). PC-3/M cells [62] were
kindly provided by Dr. Isaiah Findler, and PC-3/luc cells were
described in [42]. All cells were grown in an atmosphere of 5%
CO2, 95% humidity at 37uC in RPMI 1640 or DMEM
supplemented with 10% fetal bovine serum, 1 mM sodium
pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin,
2 mM L-glutamine and 0.1 mM non-essential aminoacids (PAA,
Pasching, Austria). PC-3/luc cells were grown in complete
medium supplemented with 200 mg/mL Geneticin (Sigma,
Alcobendas, Spain) to maintain integrated copies of the luciferase
gene.
Chemosensitization assays in mammalian cells
HeLa and PC-3 cells were treated with varying concentrations
of doxorubicin or etoposide, together, or not, with 100 mMo f
compound Ia. Viable cell numbers were determined at 24, 48 and
72 hours with the CyQuant assay.
In vivo ubiquitylation of PCNA
HEK293T cells, transfected with pcDNA-HA-UbK63, were
incubated overnight with 100 mM of compound Ia, followed by
UV irradiation (60 J/m
2). After 6 h, cells were harvested,
immunoprecipitated with anti-PCNA (Santa Cruz Biotechnology,
Santa Cruz, CA), immune complexes resolved by SDS-PAGE and
immunoblotted with anti-HA rat monoclonal antibody (Roche,
Mannheim, Germany). As a loading control, immunoprecipitates
were immunoblotted with anti-PCNA.
NF-kB assays
To determine IkB protein levels, HeLa cells were incubated
overnight with compound Ia, and treated with TNF-a (20 ng/mL)
for 15 min. Cells were lysed and analyzed by Western blotting
with anti-IkB (Cell Signaling, Danvers, MA). To analyze IKKa/b
phosphorylation, the same lysates as above were tested by Western
blotting with an antibody to phospho-IKKa (Ser180)/b (Ser181),
or to total IKKa (Cell Signaling). For nuclear translocation assays,
HeLa cells grown on sterile coverslips were transfected with
pPCR3/p65-GFP, incubated overnight with varying concentra-
tions of compound Ia, and treated with TNF-a (20 ng/mL) for
30 min. Samples were fixed, counterstained with Hoechst 33258,
and images captured with a fluorescence microscope. At least 3
coverslips and 200 cells from 10 separate fields were counted and
scored for positive nuclear green flourescence. The proportion of
cells with nuclear p65-GFP in untreated cells was taken as
background. Background subtracted values were normalized
against those for cells treated with TNF-a alone.
Invasiveness assays
PC-3/luc cells (5610
4), preincubated for 24 h with compound
Ia, were resuspended in 0.1% BSA and seeded on 12-well, 8-mM
pore diameter Transwell chambers (Costar, Cambridge, MA)
coated with diluted (1:20 in H2O) growth factor-reduced Matrigel
(Beckton-Dickinson, San Jose, CA). After 24 h of incubation in the
presence of compound Ia in both chambers, cells in the top
chamber were removed, cells in the lower chamber were assayed
for luciferase activity, and cell numbers inferred from standard
luciferase-activity curves. Each condition was assayed in triplicate.
Soft agar colony formation
Melted agar (0.5%) in complete medium was placed at the
bottom of 12-well plates, allowed to solidify and overlayed with
3610
3 PC-3/M cells resuspended in 0.3% agar/complete
medium. Cells were fed three times a week with medium
containing compound Ia. After 2 weeks, wells were fixed with
0.5% glutaraldehyde, stained with 0.025% crystal violet, images
captured and analyzed with the Image J software. Only colonies
$0.1 mm diameter were scored. Each condition was assayed in
triplicate.
Tumor xenograft analyses
PC-3/luc cells (5610
5) were injected into each rear limb of male
Balb/c nu/nu mice. Tumor size was assessed by photon counts in
a ORCA-2BT instrument (Hamamatsu Photonics, Hamamatsu
City, Japan). Luciferin (16.7 mg/ml in PBS) (Promega) was
injected intraperitoneally into anestesized mice, and images
acquired for 5 min and quantitated. Light measurements were
expressed as photon counts (PHCs), and values normalized vs.
initial counts for each tumor.
Supporting Information
Supporting Methods S1
Found at: doi:10.1371/journal.pone.0011403.s001 (0.07 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0011403.s002 (0.03 MB
PDF)
Table S2
Found at: doi:10.1371/journal.pone.0011403.s003 (0.03 MB
PDF)
Figure S1 Antagonism by compounds Ia and IIa of the Ubc13-
Uev1 interaction, assayed by yeast two-hybrid. Yeast cells (AH109
strain), co-transfected with pBD-Ubc13 and pACT2-Uev1 and
grown in quadruple selection medium, were incubated overnight
with 100 mM of cyclic compounds Ia or IIa, and assayed for a-
galactosidase activity as a semiquantitative measure of strength of
interaction. Values were normalized against those of cells
incubated with a control, unrelated cyclic compound. As an
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assayed in parallel under identical treatments and conditions.
Found at: doi:10.1371/journal.pone.0011403.s004 (1.17 MB TIF)
Figure S2 Structures of lysine derivatives of cyclic compounds Ia
(A) and IIa (B). The two compounds were synthesized with a lysine
residue covalently attached to their free amide groups, as
described in Supporting Methods S1.
Found at: doi:10.1371/journal.pone.0011403.s005 (0.26 MB TIF)
Figure S3 Compound Ia does not inhibit Ubc4-dependent
polyubiquitylation of proteasome-associated components. Com-
ponents of the proteasome holoenzyme undergo K48-based
polyubiquitylation in the presence of the ubiquitin ligase Hul5
and the E2 enzyme Ubc4 in a 1-h reaction. Compound Ia does
not inhibit the formation of Ubc4-dependent high molecular
weight ubiquitin adducts at any of the concentrations tested.
DMSO denotes the addition of the solvent at the concentration
equivalent to that added when using the maximum concentration
of compound Ia used in this experiment (500 mM).
Found at: doi:10.1371/journal.pone.0011403.s006 (1.42 MB TIF)
Figure S4 Structures of fluoresceinated derivatives of cyclic
compounds Ia (A) and IIa (B). The two compounds were
synthesized with a fluoresceine isotiocyanate moiety covalently
attached to their free amide groups, as described in Supporting
Methods.
Found at: doi:10.1371/journal.pone.0011403.s007 (0.40 MB TIF)
Figure S5 Uptake by mammalian cells of fluoresceinated
compounds Ia (Ia-FITC) and IIa (IIa-FITC). HeLa cells, grown
on sterile coverslips, were incubated overnight with 100 mMo f
either Ia-FITC or IIa-FITC, and processed for immunocytochem-
istry for detection of Ubc13. As a control, HeLa cells were
incubated with unconjugated FITC.
Found at: doi:10.1371/journal.pone.0011403.s008 (4.19 MB TIF)
Figure S6 UV-induced, K63-type polyubiquitylation requires
enzymatically active Ubc13. PCNA undergoes K63-based poly-
ubiquitylation upon UV irradiation, which is inhibited by
transfection of a dominant-negative form of Ubc13 (Ubc13C87A).
HeLa cells were transfected with HA-UbK63, together, or not,
with pcDNA3.1-Ubc13C87A. After a 24-h preincubation with
compound Ia (1 mM), cells were exposed, or not, to UV radiation
(60 J/m
2), lysed, immunoprecipitated with anti-PCNA, and K63-
based polyubuiquitin chains detected by Western blotting with
anti-HA.
Found at: doi:10.1371/journal.pone.0011403.s009 (0.65 MB TIF)
Figure S7 Growth curves of HeLa cells incubated with cyclic
compounds Ia (top) or IIa (bottom). Cells were grown for up to 4
days in the presence of varying concentrations of either cyclic
compound, freshly added every 48 h, and cell numbers deter-
mined by the CyQuant procedure. Shown are average values for
each time point and treatment condition, which were done in
octuplicate.
Found at: doi:10.1371/journal.pone.0011403.s010 (7.72 MB TIF)
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